cell (OGC) component. The World Health Organization blue book classifies the "carcinoma with osteoclast-like stromal giant cells" among rare variants of invasive carcinomas of no special type (IC-NSTs) 1 ; however, OGCs can also accompany a variety of breast cancer special types (cribriform, tubular, mucinous, papillary, lobular, squamous and other metaplastic patterns 1, 2 ). Identification of giant cells populating MPCs can be challenging as they feature the same size as the micropapillae and only differ in staining (more eosinophilic cytoplasm) (Figure 1) .
Osteoclast-like giant cells are hypothesized to derive from macrophages by syncytial fusion but not by mitosis without cell division 3 ; however, the mechanism of OGC formation and accumulation in breast carcinoma is still largely unknown. 2 An open question remains about their prognostic significance: a study on metaplastic carcinomas with an OGC component reported a 5-year survival rate fairly similar to that of patients affected by IC-NST. 1 Further studies on large cohorts would be needed to definitely ascertain whether or not a diagnosis of breast carcinoma with osteoclast-like stromal giant cells may affect patient clinical outcome. 1 
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